Back to News
Market Impact: 0.35
Insilico Medicine Doses First Patient In GENESIS-IPF-3 Phase III Trial
Source: Nasdaq
Healthcare & BiotechArtificial IntelligenceTechnology & Innovation
Insilico Medicine (3696.HK) dosed the first patient in GENESIS-IPF-3, the pivotal Phase III trial of Rentosertib for idiopathic pulmonary fibrosis. The milestone advances its generative-AI-powered drug candidate into a late-stage clinical study, a meaningful de-risking step but with efficacy and regulatory outcomes still pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Biotech stocks are surging. How investors can play the new drug innovation boom
- AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio
- Nvidia's role as AI financier faces first big test as neoclouds take market hit
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- Goldman says these top tech stocks have plenty of upside ahead of earnings
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- AI Software for Buy-Side Teams: Build the Research Stack